Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer

Cryobiology

Volumn 67, Issue 2, 2013, Pages 235-240

  Yuanying, Yuan ^a   Lizhi, Niu ^a,b   Feng, Mu ^b   Xiaohua, Wang ^a   Jianying, Zeng ^b   Fei, Yao ^b   Feng, Jiang ^b   Lihua, He ^b   Jibing, Chen ^a,b   Jialiang, Li ^a,b   Kecheng, Xu ^a,b  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b Fuda Institute of Cryosurgery for Cancer   (China)

Author keywords

Chemotherapy; Combined therapy; Cryotherapy; Immunotherapy; Metastatic NSCLC

Indexed keywords

PLATINUM DERIVATIVE;

ADOPTIVE TRANSFER; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CRYOABLATION; CRYOTHERAPY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH PAIN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PETECHIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

CHEMOTHERAPY; COMBINED THERAPY; CRYOTHERAPY; IMMUNOTHERAPY; METASTATIC NSCLC;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CRYOSURGERY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; DRUG THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84883556619     PISSN: 00112240     EISSN: 10902392     Source Type: Journal    
DOI: 10.1016/j.cryobiol.2013.08.001     Document Type: Article

References (51)

1. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., Esteban E., Molinier O., Brugger W., Melezinek I., Klingelschmitt G., Klughammer B., Giaccone G. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11:521-529.
2. Chen A.P., Setser A., Anadkat M.J., Cotliar J., Olsen E.A., Garden B.C., Lacouture M.E. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J. Am. Acad. Dermatol. 2012, 67:1025-1039.
3. Chen G., Emens L.A. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol. Immunother. 2013, 62:203-216.
4. Chen J.B., Li J.L., He L.H., Liu W.Q., Yao F., Zeng J.Y., Zhang Y., Xu K.Q., Niu L.Z., Zuo J.S., Xu K.C. Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J. Gastroenterol. 2012, 18:7056-7062.
5. Chin J.L., Touma N., Pautler S.E., Guram K.S., Bella A.J., Downey D.B., Moussa M. Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J. Urol. 2003, 170:1199-1202.
6. Choudhury A., Palma M., Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin. Lung Cancer 2008, 9(Suppl. 1):S37-44.
7. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., Wu Y.L., Bover I., Begbie S., Tzekova V., Cucevic B., Pereira J.R., Yang S.H., Madhavan J., Sugarman K.P., Peterson P., John W.J., Krejcy K., Belani C.P. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
8. Eaton K.D., Martins R.G. Maintenance chemotherapy in non-small cell lung cancer. J. Natl. Compr. Cancer Netw. 2010, 8:815-821.
9. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
10. Forest V., Peoc'h M., Campos L., Guyotat D., Vergnon J.M. Benefit of a combined treatment of cryotherapy and chemotherapy on tumour growth and late cryo-induced angiogenesis in a non-small-cell lung cancer model. Lung Cancer 2006, 54:79-86.
11. Forest V., Peoc'h M., Ardiet C., Campos L., Guyotat D., Vergnon J.M. In vivo cryochemotherapy of a human lung cancer model. Cryobiology 2005, 51:92-101.
12. Forest V., Peoc'h M., Campos L., Guyotat D., Vergnon J.M. Effects of cryotherapy or chemotherapy on apoptosis in a non-small-cell lung cancer xenografted into SCID mice. Cryobiology 2005, 50:29-37.
13. Forest V., Hadjeres R., Bertrand R., Jean-Francois R. Optimisation and molecular signalling of apoptosis in sequential cryotherapy and chemotherapy combination in human A549 lung cancer xenografts in SCID mice. Br. J. Cancer 2009, 100:1896-1902.
14. Gallimore A., Godkin A. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 2008, 123:157-163.
15. Gerard C., Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol. Oncol. 2009, 3:409-424.
16. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
17. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J. Clin. Oncol. 1993, 11:1866-1872.
18. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011, 137:305-310.
19. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
20. Kovach S.J., Hendrickson R.J., Cappadona C.R., Schmidt C.M., Groen K., Koniaris L.G., Sitzmann J.V. Cryoablation of unresectable pancreatic cancer. Surgery 2002, 131:463-464.
21. Le Pivert P., Haddad R.S., Aller A., Titus K., Doulat J., Renard M., Morrison D.R. Ultrasound guided combined cryoablation and microencapsulated 5-fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging. Technol. Cancer Res. Treat. 2004, 3:135-142.
22. Levy D., Avallone A., Jones J.S. Current state of urological cryosurgery: prostate and kidney. BJU Int. 2010, 105:590-600.
23. Li H., Wang C., Yu J., Cao S., Wei F., Zhang W., Han Y., Ren X.B. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009, 11:1076-1083.
24. Liu J.G., Chen F.L., Ge C.L., Gong M.Y., Zuo H.B., Zhang J.R. Cryosurgery for treatment of subcutaneously xenotransplanted tumors in rats and its effect on cellular immunity. Technol. Cancer Res. Treat. 2011, 10:339-346.
25. Maiwand M.O., Evans J.M., Beeson J.E. The application of cryosurgery in the treatment of lung cancer. Cryobiology 2004, 48:55-61.
26. Mir L.M., Rubinsky B. Treatment of cancer with cryochemotherapy. Br. J. Cancer 2002, 86:1658-1660.
27. Mu F., Niu L., Li H., Liao M., Li L., Liu C., Chen J., Li J., Zuo J., Xu K. Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer. Cryobiology 2013, 66:76-80.
28. Niu L., Mu F., Zhang C., Li Y., Liu W., Jiang F., Li L., Liu C., Zeng J., Yao F., Chen J., Li J., Zuo J., Xu K. Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. Cryobiology 2013.
29. Niu L., Zhou L., Xu K., Mu F. Combination of cryosurgery and Iodine-125 seeds brachytherapy for lung cancer. J. Thorac. Dis. 2012, 4:504-507.
30. Niu L., Xu K., Mu F. Cryosurgery for lung cancer. J. Thorac. Dis. 2012, 4:408-419.
31. Niu L.Z., He L.H., Zhou L., Yang Z.Z., Zuo J.S., Xu K.C. Percutaneous cryoablation and (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer: report of 67 cases. Zhonghua Zhong Liu Za Zhi 2012, 34:940-944.
32. Niu L.Z., Chen J.B., Liao M.T., Yuan Y.Y., Zeng J.Y., Li J.L., Zuo J.S., Xu K.C. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas 2013.
33. Penland S.K., Socinski M.A. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin. Radiat. Oncol. 2004, 14:326-334.
34. Pergolizzi J.V., Auster M., Conaway G.L., Sardi A. Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature. Am. Surg. 1999, 65:402-405.
35. Perona R., Lopez-Ayllon B.D., de Castro Carpeno J., Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin. Transl. Oncol. 2011, 13:289-293.
36. Plate J. Clinical trials of vaccines for immunotherapy in pancreatic cancer. Exp. Rev. Vaccines 2011, 10:825-836.
37. Ren X., Yu J., Liu H., Zhang P., An X., Zhang N., Hao X. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother. Radiopharm. 2006, 21:22-33.
38. Rovere-Querini P., Manfredi A.A. Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: implications for the immunotherapy of pancreatic cancer. JOP 2004, 5:308-314.
39. Sabel M.S. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009, 58:1-11.
40. Sangiolo D., Martinuzzi E., Todorovic M., Vitaggio K., Vallario A., Jordaney N., Carnevale-Schianca F., Capaldi A., Geuna M., Casorzo L., Nash R.A., Aglietta M., Cignetti A. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int. Immunol. 2008, 20:841-848.
41. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
42. Schnurr M., Scholz C., Rothenfusser S., Galambos P., Dauer M., Robe J., Endres S., Eigler A. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 2002, 62:2347-2352.
43. Sharma A., Moore W.H., Lanuti M., Shepard J.A. How I do it: radiofrequency ablation and cryoablation of lung tumors. J. Thorac. Imaging 2011, 26:162-174.
44. Shi S.B., Ma T.H., Li C.H., Tang X.Y. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012, 98:314-319.
45. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991, 9:271-296.
46. Thanendrarajan S., Nowak M., Abken H., Schmidt-Wolf I.G. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk. Res. 2011, 35:1136-1142.
47. Xu K.C., Niu L.Z., He W.B., Guo Z.Q., Hu Y.Z., Zuo J.S. Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J. Gastroenterol. 2003, 9:2686-2689.
48. Xu K.C., Niu L.Z., Zhou Q., Hu Y.Z., Guo D.H., Liu Z.P., Lan B., Mu F., Li Y.F., Zuo J.S. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J. Gastroenterol. 2009, 15:3664-3669.
49. Yang L., Ren B., Li H., Yu J., Cao S., Hao X., Ren X. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol. Immunother. 2013, 62:65-73.
50. Zhang Y.S., Yuan F.J., Jia G.F., Zhang J.F., Hu L.Y., Huang L., Wang J., Dai Z.Q. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J. Gastroenterol. 2005, 11:3339-3345.
51. Zhou P., Liang P., Dong B., Yu X., Han Z., Xu Y. Phase clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol. Ther. 2011, 11:450-456.